Skip to main content
Newsroom

News & Media Coverage

Press Releases

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders
Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference
Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022
Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies
Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference
Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Enveric Biosciences Appoints New Independent Directors
Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules
Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines
Enveric Biosciences Announces Reverse Stock Split
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio
Enveric Biosciences to Participate in Upcoming Conferences in June 2022
Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022
Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022
Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress
Enveric Biosciences Announces Closing of $10 Million Public Offering
Enveric Biosciences Announces Pricing of $10 Million Public Offering
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 – Cannabinoid + Celecoxib Conjugate
Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer
Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate
Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF
Enveric Biosciences to Participate in Wonderland: Miami Conference
Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021
Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its ‘Psybrary’ of Psychedelic Molecular Compounds
Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021
Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
Enveric Biosciences Announces MagicMed Industries’ Presentations at the Following Investor Conferences in September
Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders
Enveric Biosciences Announces Approval from Israel’s Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma
Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences
Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives
Enveric Biosciences Reports First Quarter 2021 Financial Results
Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board
Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st
Enveric Biosciences Appoints Carter Ward as Chief Financial Officer
Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021
Enveric Biosciences Appoints Dr. Douglas D. Lind to Company’s Board of Directors
Enveric Biosciences to Participate in Upcoming Investor Conferences in March
Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech
Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs
Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock
Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering
Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies
Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering
Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors

Media Coverage

NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics
Enveric Offers Investors Rare Exposure To Both Cannabis And Psychedelic Industries [Benzinga]
Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]
Inside the Race to Make Psychedelics ‘Mainstream Medicines’ [NXT Psychedelics]
Five Companies Developing Second Generation Psychedelics For Mental Health [Benzinga]
Groundbreaking Trial to Explore Psychedelic Therapy for Cancer Distress [Psychedelic Health]
UCalgary to Collaborate on Clinical Trial Assessing Psychedelic Treatments and Cancer Related Distress [The Edmonton Journal]
Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary [via Benzinga]
Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis [Benzinga]
Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis [IPO Edge]
How AI Could Unlock the Medical Potential of Psychedelics
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of [Vice]
Here’s What Happens When Psychedelics Meets AI [Green Market Report]
Enveric Names New Chief Medical Officer [Green Market Report]
This Isn’t the 60s Again’: Psychedelics Business Takes Off Amid Culture Clash [The Guardian]
What Did You Miss at This Year’s Wonderland Psychedelic Conference? [Cannabis & Tech Today]
Enveric Biosciences’ CBD-Based Product Reduces Dermatitis Severity In Animal Study [Benzinga]
Enveric Biosciences Sees Opportunity In Both Cannabinoids, Psychedelics [Green Market Report]
CBD News Roundup: Study Shows Effectiveness of CBDistillery Sleep Product [CBD Insider]
Highlights on Enveric Biosciences [Psychedelic Spotlight]
Interview with Dr. Robert Wilkins of Enveric Biosciences [Thrive Global]
Enveric Enters Next Phase Of CBD Cancer Treatment Trial [Candid Chronicle]
Enveric Biosciences and MagicMed [The Green Rush Podcast]
Enveric Biosciences – Clinical Development of Cannabinoids and Psychedelics [Health Professionals Radio]
Texas the Latest State to Legalize Psychedelic Medical Research [Bloomberg Law]
Enveric Biosciences + MagicMed on Recent Acquisition Announcement, Mind and Body Clinical Pipeline [SNN]
Exclusive: MagicMed CEO On Psychedelics Company’s ‘Secret Sauce,’ M&A Deal With Enveric Biosciences [Benzinga]
Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility [Benzinga]
Enveric Biosciences Buys MagicMed In All Inventory Deal Valued At $30 Million [Marijuana Mag]
Enveric Moves to Acquire MagicMed, Form Latest Nasdaq-Listed Psychedelics Company [Truffle Report]
Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries [Psychedelic Spotlight]
MagicMed: Finding the Derivative with Dr. Joseph Tucker [Psychedelic Invest]
Enveric Biosciences Buys MagicMed In All Stock Deal Valued At $30 Million [The Green Market Journal]
MagicMed to Be Acquired by Nasdaq-Listed Company [Psilocybin Alpha]
Another Psychedelics Company Joins ‘Exclusive Nasdaq Group’ With Enveric’s Acquisition Of MagicMed Industries [Benzinga]
Happy Employees = Happy Shareholders [Fortune]
Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma [Cancer Network]
Enveric Biosciences CEO Describes How the Group Has ‘Multiple Shots on Goal’ with Current Pipeline [Proactive Investors]
David Johnson, Chairman and CEO of Enveric Biosciences [The Green Rush Podcast]
Enveric’s Patient-Centric Model to Enhance the Quality of Life of Cancer Patients [Benzinga]
Enveric Biosciences on Acquisition of Exclusive License from Diverse Biotech and Value Catalysts [SNN]
Enveric Biosciences Signs Licensing Agreement with Diverse Biotech [Pharmaceutical Business Review]
Enveric Biosciences Acquires License for Diverse Biotech’s Novel Molecules [Pharmaceutical Technology]
Enveric Biosciences Stock Skyrockets After Licensing Agreement With Diverse Biotech [Benzinga]
CBD-focused Enveric Biosciences Stock Soars on Heavy Volume After License Deal with Cancer Treatment Company [Market Watch]
Rising High: An Exclusive Talk with Biotech Company Enveric Biosciences [The Fly]
Jazz Leaps into Epilepsy with $7.2B Buyout of Cannabinoid Drugmaker GW Pharma [Fierce pharma]
Cannabis Stocks Rally Anew as $7 Billion GW Pharma Deal Spurs Interest in Weed and its Medical Benefits [MarketWatch]
Medical cannabinoids (CBD) and brain tumours – Interview with Dr. Wai Liu (via Brain Tumour Research)
Cannabis Executives Reveal The Industry’s 2019 Challenges And A Few Opportunities Too
Cannabidiol (CBD) oil as a treatment for brain tumours (via Brain Tumour Research)
Dr. Wai Liu and the effect of cannabis on cancer (via ITV News)
A compound in cannabis is ‘significantly’ effective in destroying cancerous tumours in leukaemia, study reveals (via The Daily Mail)
Marijuana destroys leukemia cells, says totally chill new study (via Maxim)
Cannabinoids used in sequence with chemotherapy are a more effective treatment for cancer, say experts (via Science Daily)
Cannabinoids shown to enhance tumor-killing effects of chemotherapy drugs (via New Atlas)
How pot helped shrink one of the most aggressive brain cancers (via The Washington Post)
How cannabis was used to shrink one of the most aggressive brain cancers (via The Conversation)
Research into cannabinoids’ anti-cancer potential in Britain (via Charlotte Foot)

Media Contact

Valter Pinto
KCSA Strategic Communications
EnvericBio@kcsa.com
(212) 896-1254

Subscribe to Receive News Alerts



© 2022 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.